Agreed, heterogeneity across lesions is real, but I think this argues for combination mechanisms rather than against them. If anything, heterogeneity makes a multi-mechanism approach like this (of the CAR plus ADCC) more plausible than a single-agent effect.
That they had both reductions in LDH and CEA is a strong early signal, but not unprecedented with effective therapy - just uncommon in (late-line) mMSS CRC. This an early systemic readout of cancer cell targeting and tumour shrinkage.
Market Data 
Markets 
AI
